Cefozopran
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00735 |
| CAS | 113359-04-9 |
| Molecular Weight | 515.53 |
| Molecular Formula | C19H17N9O5S2 |
| Purity | >98% |
Online Inquiry
Description
It is produced by the strain of Semisynthetic fourth generation cephalosporin for injection.
Specification
| Related CAS | 113981-44-5 (hydrochloride) |
| Synonyms | cefozopranum |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | CON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)CN4C=C[N+]5=C4C=CC=N5)C(=O)[O-] |
| InChI | InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11+/t12-,17-/m1/s1 |
| InChI Key | QDUIJCOKQCCXQY-HEOFFLBTSA-N |
Properties
| Appearance | Colorless Powder |
| Melting Point | > 300 °C |
| Density | 1.59 g/cm3 |
Reference Reading
1.[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2008)].
Goto H, Iwasaki M. Jpn J Antibiot. 2015 Feb;68(1):19-36.
From October 2008 to September 2009, we collected the specimen from 374 patients with lower respiratory tract infections in 15 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 423 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, 421 strains were examined. The isolated bacteria were: Staphylococcus aureus 78, Streptococcus pneumoniae 78, Haemophilus influenzae 89, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 19, Klebsiella pneumoniae 28, and Moraxella catarrhalis 32. Of 78 S. aureus strains, those with 2 μg/mL or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 μg/mL or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 34 (43.6%) and 44 (56.4%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all strains at 0.
2.[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2009)].
Goto H, Kumagai S. Jpn J Antibiot. 2015 Feb;68(1):37-54.
From October 2009 to September 2010, we collected the specimen from 432 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. All of 479 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, were examined. The isolated bacteria were: Staphylococcus aureus 90, Streptococcus pneumoniae 74, Haemophilus influenzae 82, Pseudomonas aeruginosa (non-mucoid) 60, P. aeruginosa (mucoid) 31, Klebsiella pneumoniae 41, and Moraxella catarrhalis 34. Of 90 S. aureus strains, those with 2 μg/mL or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 μg/mL or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 43 (47.8%) and 47 (52.2%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all strains at 0.
3.Case of late-onset bleb associated endophthalmitis caused by Rothia mucilaginosa.
Oie S1, Mochizuki K1, Ishida K2, Nakayama A3, Ohkusu K4. J Infect Chemother. 2016 Mar 18. pii: S1341-321X(16)00056-8. doi: 10.1016/j.jiac.2016.02.007. [Epub ahead of print]
Rothia mucilaginosa is a gram-positive coagulase-negative coccus of the family Micrococcaceae. Although R. mucilaginosa forms part of the oropharyngeal microflora, it has only recently been isolated in ocular infections. We report a case of a 41-year-old man who developed late-onset bleb-related endophthalmitis (BRE). He had undergone glaucoma surgery 21 years earlier and had a thin-walled cystic bleb prior to the development of endophthalmitis in his right eye. He immediately received intravitreal injections of ceftazidime and vancomycin, topical levofloxacin and cefmenoxime, and intravenous cefozopran. Culture of the aqueous humor specimen identified R. mucilaginosa by 16S rRNA sequence analysis. To our knowledge, this is the first report of late-onset BRE caused by R. mucilaginosa. Our case indicates that R. mucilaginosa can be a cause of late-onset BRE, and that molecular analysis is an accurate method to identify R. mucilaginosa.
4.[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2010)].
Goto H, Iwasaki M. Jpn J Antibiot. 2015 Apr;68(2):85-104.
From October 2010 to September 2011, we collected the specimen from 361 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. All of 399 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in infection, were examined. The isolated bacteria were: Staphylococcus aureus 70, Streptococcus pneumoniae 65, Haemophilus influenzae 72, Pseudomonas aeruginosa (non-mucoid) 47, P. aeruginosa (mucoid) 14, Klebsiella pneumoniae 30, and Moraxella catarrhalis 39. Of 70 S. aureus strains, those with 2 μg/mL or less of MIC of oxacillin (methicillin-susceptible S. aureus: MSSA) and those with 4 μg/mL or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) were 45 (64.3%) and 25 (35.7%) strains, respectively. Against MSSA, imipenem had the most potent antibacterial activity and inhibited the growth of all strains at 0.
Recommended Products
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
